As the single-receptor pharmacotherapies have been recently found to have modest therapeutic value on alcohol relapse, there is an obvious need for better efficacy [18,20], and our new finding here has provided promising in vivo data demonstrating that the clinically developed short-acting KOR antagonist aticaprant, in combination with low-dose naltrexone, may offer a novel strategy to treat alcohol relapse. Here, OPRK1 is linked to alcohol dependence.